Stocktoria

RESMED INC RMD

NYSE · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1995-06-01 · LEI

RESMED INC (RMD) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.20% (safety: safe). FY2025 revenue was $5.7B at a 26.9% net margin.

Chart by TradingView
92/100
Stocktoria Quality Score · grade A+
8/9
Piotroski F — financial health
8.65
Altman Z″ — distress risk · safe
0.9%
Dividend yield 5y avg · safe · Dividend payout 22.2%
-2.59
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
6 6 4 8 5 5 3 7 8 7 2017201820192020202120222023202420252026
Altman Z″
6.79 7.11 4.89 5.77 5.97 7.26 6.40 7.58 8.65 9.10 2017201820192020202120222023202420252026

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$222.00 as of 2026-09-01 · -18.9% 1y
$190.57$273.7352-wk

Beneish M-score: -2.59 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$29.1B
P / E19.1×
Dividend yield 5y avg0.9%
Net margin 5y avg23.8%
Return on equity 5y avg22.5%
Beta0.77
Employees11,370

Analyst price target

$250.22 +12.7% vs last
consensus: buy · 17 analysts
target range $175.00 – $320.00 · median $235.00
2 strong buy · 7 buy · 10 hold · 1 sell
Recent analyst actions
DateFirmRating
2026-09-15RBC CapitalOutperform (up)
2026-08-31KeybancOverweight (main)
2026-08-19Rothschild & CoNeutral (init)
2026-08-07RBC CapitalSector Perform (main)
2026-08-07Piper SandlerNeutral (main)
2026-08-07KeybancOverweight (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$13.23
Forward P / E16.8×

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Smart money · insiders, last 12 months

Insiders net sold -$5.8M on the open market · 8 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 2036 companies

Piotroski Fstronger than 97%
Net marginstronger than 95%
Return on equitystronger than 91%
Revenue growthstronger than 63%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 8/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.304
Retained earnings / assets0.744
EBIT / assets0.206
Equity / liabilities2.705

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
RMDRESMED INC8/98.6519.1+9.9%
DXCMDEXCOM INC7/94.9832.4+15.6%
MMEDMiniMed Group, Inc.3/94.28—+14.3%
WSTWEST PHARMACEUTICAL SERVICES INC7/99.3447.2+6.3%
SOLVSolventum Corp6/92.348.9+0.9%
GMEDGLOBUS MEDICAL INC7/910.0621.8+16.7%
PODDINSULET CORP6/94.7844.4+30.7%

All Manufacturing companies →

About RESMED INC

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

FAQ

Is RMD financially healthy?

RESMED INC's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does RMD pay a dividend, and is it safe?

Yes. RESMED INC pays a dividend yielding about 1.20% with a 22.2% payout ratio, rated “safe” for safety.

How profitable is RMD?

In FY2025, RESMED INC had a net margin of 26.9% and a return on equity of 23.1%.

Is RMD overvalued or undervalued?

RESMED INC trades at about 21.3× trailing earnings — below its 10-year norm (10-year range 20.2×–83.9×, median 45.4×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for RMD?

The average Wall-Street price target for RESMED INC is $250.22, about 12.7% above the recent price, from 17 analysts (consensus: buy).

Is RMD a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on RESMED INC: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 19.1×, a dividend yield of 1.20%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.